How Is HSV Spread Through Skin and Sexual Contact

Herpes simplex virus spreads primarily through direct contact between infected skin or mucous membranes and the skin or mucous membranes of another person. This includes kissing, vaginal sex, anal sex, oral sex, and any genital-to-genital or mouth-to-genital touching. What makes HSV particularly effective at spreading is that the virus sheds from skin that looks completely normal, so transmission frequently happens when neither partner knows the virus is present. Understanding the specific biological steps involved, from how the virus enters cells to why it reactivates unpredictably, helps explain both why HSV is so common and what actually reduces the risk of passing it on.

How the Virus Gets Into Your Skin Cells

HSV doesn’t just land on skin and immediately cause infection. The virus needs access to living cells beneath the outermost dead layers of skin. Intact, thick skin on your arm or leg is a poor entry point. The virus preferentially targets mucosal surfaces, like the lining of the mouth, genitals, or anus, and thin skin areas where micro-abrasions or small breaks are common. Once it reaches viable cells, the virus first attaches to sugar molecules on the cell surface, which triggers a chain of interactions between viral proteins and host cell receptors that ultimately lets the virus fuse with the cell membrane and inject its genetic material inside.¹

The virus uses a set of surface proteins, particularly one called gB acting alongside gD and a gH/gL pair, as its “fusion machinery” to merge its outer envelope with the host cell.² The main cells it infects first are keratinocytes, the dominant cell type in the outer layer of skin and mucosal tissue. Interestingly, HSV uses different doors depending on the cell type. In keratinocytes, it enters through a process that requires an acidic environment inside cell compartments, while in nerve cells it takes a more direct route through the cell surface.³ This dual-entry ability is part of what makes HSV so successful: it can infect both the skin where it first lands and the nerve endings it needs to reach for long-term survival.

Why the Infection Never Goes Away

After infecting the surface cells, HSV travels along nerve fibers in the reverse direction, heading from the skin back toward clusters of nerve cell bodies near the spine called dorsal root ganglia. There the virus goes dormant, hiding its genetic material inside neurons where the immune system has limited reach.⁴ This latency is lifelong. No current treatment can clear the virus from these nerve cells.

Periodically, something triggers the virus to wake up. Stress, illness, UV exposure, and hormonal changes are commonly cited triggers, though reactivation also happens spontaneously without any obvious cause. When the virus reactivates, new virus particles travel back down the nerve fibers toward the skin surface, a process that happens rapidly along the internal scaffolding of the nerve cell.⁵ Sometimes this produces a visible sore. Often, however, the virus reaches the skin and is shed without causing any noticeable lesion at all.

Asymptomatic Shedding and Why It Matters for Transmission

This is the piece most people don’t fully appreciate: the majority of HSV transmission happens when the infected person has no visible outbreak. The virus can be present on the skin surface in quantities high enough to infect a partner even when the skin looks and feels normal.

A study tracking people with genital HSV-2 found that the virus was detectable on genital skin on about 12% of days when no lesions were present. People who had never had a recognized outbreak still shed the virus on roughly 9% of days without symptoms.⁶ The amount of virus detected during these silent shedding episodes was essentially the same regardless of whether the person had ever had a recognized outbreak, which means asymptomatic carriers can be just as contagious on any given shedding day.

Genital HSV-1 shedding follows a somewhat different pattern. In the first year after infection, people with a primary genital HSV-1 infection shed the virus on about 17% of days, with the vast majority of that shedding occurring without symptoms. By the second sampling period later in the year, that rate dropped to around 9%.⁷ Genital HSV-1 tends to shed less frequently than genital HSV-2 over time, which is one reason genital-to-genital HSV-1 transmission is less common than HSV-2.

Viral Load and When Transmission Actually Happens

Not every moment of shedding carries the same risk. Modeling work suggests that transmission is unlikely when the amount of virus on the skin stays below about ten thousand DNA copies. Most actual transmission events happen during prolonged shedding episodes with high viral quantities. Here’s the clinically frustrating part: many of these high-shedding episodes still don’t produce a visible ulcer, or the ulcer is so small it goes unnoticed.⁸ This means that simply avoiding sex during visible outbreaks reduces risk but doesn’t eliminate it.

The location of shedding also matters. In men, the penile shaft is the most common site for HSV shedding. In women, the virus sheds from multiple genital areas including the vulva and perianal region. These anatomical differences have real consequences for how well barrier methods work, as discussed below.

The Initial Infection Site and How HSV Spreads Within Tissue

When HSV reaches mucosal tissue, the first cells hit are usually keratinocytes and certain immune cells in the skin. Research on human foreskin tissue has shown that after the initial infection, the virus spreads rapidly through the mid-layers of keratinocytes. Infected cells release signaling molecules that actually rearrange receptors on the surface of neighboring cells, making those neighbors easier for the virus to infect.⁹ In other words, the virus actively remodels the tissue around it to favor its own spread. This is why initial outbreaks can expand quickly once they start.

Your body does fight back at the skin level. Specialized immune cells called CD8αα+ T cells take up permanent residence at the dermal-epidermal junction, the boundary between the outer and inner layers of skin, at sites where HSV has previously reactivated. These cells remain active and produce antiviral molecules even during quiet periods between outbreaks. When the virus begins reactivating, a high local concentration of these T cells can shut down the episode before it produces symptoms.¹⁰ This is partly why recurrent outbreaks tend to be milder and shorter than the first episode: the immune system has already stationed sentries at the usual trouble spots.

Condoms Reduce Risk but Don’t Eliminate It

Condoms are consistently recommended for HSV prevention, and they do help, but their effectiveness varies in ways that matter. A pooled analysis found that consistent condom use reduced the risk of acquiring HSV-2 by about 30% overall, and each additional unprotected sex act measurably increased the cumulative risk.¹¹

The direction of transmission matters a lot. One study found that condoms reduced the per-act risk of male-to-female HSV-2 transmission by about 96%, but the reduction from female-to-male transmission was a more modest 65% and did not reach clear statistical significance.¹² The reason for this gap comes down to anatomy. Since the penile shaft is the most common shedding site in men, a condom covers it well. But women shed from the vulva and perianal area, which a male condom doesn’t cover, so men remain exposed to those surfaces during sex.¹³

This doesn’t mean condoms aren’t worth using. Even partial protection compounds over time, especially in ongoing sexual relationships where cumulative exposure adds up. But the evidence is clear that condoms alone are not a complete solution for HSV prevention.

Antiviral Suppressive Therapy

Daily antiviral medication taken by the infected partner meaningfully reduces both shedding and transmission. In a large trial of couples where one partner had HSV-2, daily valacyclovir cut the frequency of detectable genital shedding from about 11% of days to about 3% of days. The rate of overall HSV-2 acquisition by the uninfected partner dropped by roughly half, and the rate of symptomatic infection dropped by 75%.¹⁴

Combining daily antivirals with consistent condom use provides additive protection. In practice, couples where the HSV-positive partner takes daily suppressive therapy and both partners use condoms bring the annual transmission risk down substantially, though not to zero. Some shedding still occurs on antiviral therapy, and the brief, high-copy episodes that drive transmission can still break through.

Autoinoculation and Spreading It to Other Parts of Your Own Body

You can, in theory, spread HSV from one site on your body to another, a process called autoinoculation. This is most likely during a primary infection, when your immune system hasn’t yet built up antibodies against the virus. Touching an active cold sore and then rubbing your eye, for instance, could introduce the virus to the eye. Once you have established antibodies, the risk of self-transfer drops significantly but doesn’t disappear entirely, particularly in people who are immunocompromised.¹⁵ Basic hygiene during outbreaks, like handwashing after touching a sore, is the practical prevention measure here.

Can You Catch HSV From Objects or Surfaces?

This question comes up constantly, and the honest answer is that it’s theoretically possible but practically rare. HSV can survive outside the body for short periods: up to about two hours on skin, three hours on cloth, and four hours on plastic surfaces.¹⁶ However, the virus degrades quickly in the environment, and transmission requires both a sufficient quantity of viable virus and contact with a susceptible mucosal or broken-skin surface. The overwhelming consensus is that HSV spreads through person-to-person contact, not through shared towels, toilet seats, or drinking glasses, though those fears are understandably common.

Mother-to-Child Transmission

HSV can pass from a mother to her baby, primarily during vaginal delivery when the baby contacts the genital tract. The risk varies enormously depending on the timing of the mother’s infection. Women who acquire genital herpes for the first time near delivery pose the highest risk to the infant, because they haven’t yet developed antibodies that would partially protect the baby.¹⁷ In one large study, the absence of maternal antibodies to the specific HSV type being shed was associated with a dramatically higher risk of transmission to the newborn.¹⁸ Women with longstanding herpes who experience a recurrence near delivery have a much lower risk, because their antibodies cross the placenta and offer the baby some protection. Cesarean delivery and antiviral therapy near term are the standard approaches to reduce neonatal risk when active genital herpes is present.

Skin Conditions That Increase Vulnerability

Not everyone’s skin barrier is equally protective. People with atopic dermatitis (eczema) face a measurably higher risk of HSV infection. A large population-based study found that both children and adults with eczema had a 50–52% greater risk of herpes simplex infection compared to people without eczema, and the risk rose in step with disease severity.¹⁹ In severe cases, HSV can spread across large areas of eczema-affected skin in a condition called eczema herpeticum, which requires urgent medical treatment. The compromised skin barrier in eczema, with its reduced antimicrobial peptides and disrupted lipid layers, gives the virus easier access to the living cells it needs to infect.

The vaginal microbiome also plays a role in genital HSV susceptibility. Research has linked bacterial vaginosis and non-Lactobacillus-dominant vaginal flora to greater vulnerability to HSV-2, through mechanisms that include weakened mucosal barrier integrity and altered immune signaling at the tissue surface.²⁰ This connection is still being worked out at the molecular level, but it reinforces the broader point that anything compromising the mucosal barrier makes HSV transmission easier.

The HSV-HIV Connection

HSV-2 and HIV have a well-documented synergistic relationship. Having genital herpes roughly triples the risk of acquiring HIV. The mechanism is two-pronged: HSV-2 reactivation causes both visible ulcers and microscopic disruptions in the mucosal lining, and at the same time it recruits exactly the immune cells that HIV targets, like CD4+ T cells and macrophages, to the genital tissue.²¹ So HSV-2 simultaneously opens the door and fills the room with the cells HIV wants to infect. This interaction is a significant driver of HIV transmission in regions where both infections are common.

Does Having HSV-1 Protect Against HSV-2?

There’s a popular assumption that if you already have cold sores (typically HSV-1), you’re protected from genital herpes (typically HSV-2). The reality is more nuanced. Epidemiological data does show a negative association between HSV-1 and HSV-2 infections, suggesting that prior HSV-1 infection offers some protection against acquiring HSV-2.²² Animal studies have confirmed a small but real survival benefit from pre-existing HSV-1 immunity when challenged with HSV-2, but the protection is partial. Mice with prior HSV-1 exposure still showed signs of disease after HSV-2 infection, consistent with human experience where prior HSV-1 may reduce the severity of HSV-2 symptoms without preventing infection outright.²³ So having HSV-1 doesn’t make you immune to HSV-2, but it might make an HSV-2 infection less clinically severe if you do catch it.

Where Vaccine Development Stands

Given how many people HSV affects and how difficult it is to prevent with behavioral measures alone, an effective vaccine would be transformative. So far, the results have been disappointing. Two vaccine candidates have made it through large-scale clinical trials. One, based on HSV-2 surface proteins combined with an immune-stimulating adjuvant, generated strong antibody responses but provided no protection against either acquiring HSV-2 or developing genital ulcers. A second candidate, using a different adjuvant designed to stimulate a different arm of the immune response, did show protection, but only in women who were already negative for both HSV-1 and HSV-2, a narrow population.²⁴

The failure of antibody-heavy approaches has pushed researchers toward vaccine designs that emphasize T-cell immunity, especially at mucosal surfaces. The discovery that tissue-resident CD8αα+ T cells play a central role in containing HSV reactivation at the skin level has opened new avenues. Several next-generation vaccine candidates are in earlier stages of development, including mRNA-based platforms and live-attenuated approaches, though none have yet produced the broad, durable protection needed to change the landscape of HSV prevention. For now, the practical toolkit remains condoms, antivirals, and honest communication between partners.